Skip to main
BMEA
BMEA logo

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. is advancing its clinical pipeline with promising results from its principal drug candidate, icovamenib, which has shown durable, clinically meaningful reductions in HbA1c over 52 weeks in type 2 diabetes subgroups, highlighting significant efficacy in severe insulin-deficient patients. The company has also initiated Phase I trials for its next-generation oral GLP-1 receptor agonist, BMF-650, which demonstrated promising preclinical results, including notable weight reductions and appetite suppression in obese models. Furthermore, while the company reported a net loss of $16.4 million in Q3 2025, this reflects a significant improvement compared to the net loss of $32.8 million in the same quarter the previous year, indicating a trajectory towards better financial health while continuing to invest in its innovative drug development pipeline.

Bears say

Biomea Fusion Inc reported a decrease in research and development (R&D) expenses, totaling $14.4 million in Q3 2025, down from $27.2 million in the same quarter of the previous year, indicating potential challenges in ongoing clinical trials or project advancements. General and administrative (G&A) expenses also saw a decline to $4.2 million from $6.8 million, suggesting cost-cutting measures that may reflect financial strain. Furthermore, the reduction in the price target from $16.00 to $12.00 highlights a less favorable outlook on the company's financial performance and market position.

BMEA has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 7 analysts, BMEA has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.